Stay updated on Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial
Sign up to get notified when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.

Latest updates to the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.7%
- Check13 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific state, country, and city information. This indicates a shift towards a more generalized presentation of location data.SummaryDifference25%
- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.3%
- Check35 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.3%
- Check42 days agoChange DetectedThe page now includes a disclaimer about the U.S. government's lack of review for the safety and science of studies listed, and it notes the termination of the drug Flotetuzumab for certain conditions. Additionally, the HHS Vulnerability Disclosure section has been added.SummaryDifference100%
- Check49 days agoChange DetectedThe webpage has removed important disclaimers regarding the U.S. government's review of clinical studies and the termination of a specific drug study, while adding a note about server errors and a reminder about the official nature of the website.SummaryDifference100%
Stay in the know with updates to Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.